Merkel Cell Carcinoma Clinical Trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For Merkel cell carcinoma patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

  • Below is a list of Merkel cell carcinoma clinical trials that are currently open and accepting patients at SCCA.
  • For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 4 of 4 trials.

TTI-621 in Percutaneously-Accessible Solid Tumors and Mycosis Fungoides (UW16042)

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

View Trial
Investigator:
John A. Thompson
, MD
Status:
Recruiting
Study ID:
NCT02890368
Nivolumab for Virus-Associated Tumors

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects With Virus-Positive and Virus-Negative Solid Tumors

View Trial
Investigator:
Shailender Bhatia
, MD
Status:
Recruiting
Study ID:
NCT02488759
Neukoplast Infusions with Unresectable Stage III or Distant Metastatic Merkel Cell Carcinoma (20150886)

Phase II Study of Neukoplast (NK-92) Infusions in Patients with Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)

View Trial
Investigator:
Shailender Bhatia
, MD
Status:
Recruiting
Study ID:
NCT02465957
Avelumab (MSB0010718C) for Merkel Cell Carcinoma (UW14024)

A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects With Merkel Cell Carcinoma

View Trial
Investigator:
Shailender Bhatia
, MD
Status:
Recruiting
Study ID:
NCT02155647